Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Core Viewpoint - The market anticipates Alnylam Pharmaceuticals (ALNY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - Alnylam is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year change of -105.4% [3]. - Revenues are projected to be $671.11 million, which is a 1.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 62.96% higher in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +831.25% suggests that analysts have recently become more optimistic about Alnylam's earnings prospects [12]. Earnings Surprise History - In the last reported quarter, Alnylam was expected to post a loss of $0.56 per share but actually reported a loss of -$0.01, resulting in a surprise of +98.21% [13]. - Over the past four quarters, Alnylam has beaten consensus EPS estimates three times [14]. Industry Comparison - Incyte (INCY), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $1.4 per share for the same quarter, indicating a year-over-year change of +176.9% [18]. - Incyte's revenues are expected to reach $1.15 billion, up 10.3% from the previous year [18].